<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526253</url>
  </required_header>
  <id_info>
    <org_study_id>BMI-WW-02-003</org_study_id>
    <nct_id>NCT00526253</nct_id>
  </id_info>
  <brief_title>To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction</brief_title>
  <acronym>MARVEL</acronym>
  <official_title>A Multicenter Study to Assess the Safety and Cardiovascular Effects of Myocell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioheart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioheart, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study injects a person's own stem cells into heart muscle tissue after a person has one&#xD;
      or more heart attacks. The purpose of the study is whether the stem cells will improve a&#xD;
      patient's heart performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous myoblasts are harvested from a patient's skeletal muscle tissue. The myoblasts are&#xD;
      isolated and expanded in culture in a closed system. When a sufficient number of cells are&#xD;
      estimated they are taken from culture, packaged in a suspension and sent to the patient's&#xD;
      interventionalist. The interventionalist uses an injection catheter via femoral artery to&#xD;
      inject the myoblasts directly into the myocardium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization occurrences</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MyoCell</intervention_name>
    <description>Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MyoCell</intervention_name>
    <description>Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypothermosol</intervention_name>
    <description>After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible patients must meet ALL of the following inclusion criteria during the&#xD;
        screening/enrollment visit #1 and prior to being randomized into the study.&#xD;
        Screening/enrollment visit #1 is defined to start the date the ICF is signed by the&#xD;
        patient:&#xD;
&#xD;
          1. Chronic CHF, New York Heart Association (NYHA) Class II-IV;&#xD;
&#xD;
          2. Stable and on optimal medical management for greater or equal to 60 days as follows:&#xD;
&#xD;
               1. systolic and diastolic hypertension controlled in accordance with contemporary&#xD;
                  guidelines;&#xD;
&#xD;
               2. patient stabilized on maximum tolerated dose of beta blockers;&#xD;
&#xD;
               3. patient stabilized on maximum tolerated dose of angiotensin concerting enzyme&#xD;
                  (ACE) inhibitors;&#xD;
&#xD;
               4. patients intolerant of ACE inhibitors should be stabilized on angiotensin&#xD;
                  receptor blockers (ARB);&#xD;
&#xD;
               5. fluid control with diuretics and a salt restricted diet;&#xD;
&#xD;
               6. patients with sever symptoms of heart failure (Class III-IV) lacking&#xD;
                  contraindications to aldosterone antagonism and not on both ACE inhibitors and&#xD;
                  ARBs have been considered for such therapy.&#xD;
&#xD;
          3. Age 18-80;&#xD;
&#xD;
          4. Left ventricular ejection fraction (LVEF) at screening of less than or equal to 35&#xD;
             percent by multiple gaited acquisition scan (MUGA);&#xD;
&#xD;
          5. Need or feasibility for revascularization has been ruled out by previous coronary&#xD;
             angiogram or ruled out to the satisfaction of the investigator via previous&#xD;
             conventional stress study completed within 1 year of screening. The need or&#xD;
             feasibility for revascularization will be reassessed at screening using dobutamine&#xD;
             stress echocardiography (DSE);&#xD;
&#xD;
          6. Defined region of mycardial dysfunction related to previous MI involving the anterior,&#xD;
             later, posterior or inferior walls including the apical septum (excluding the basal&#xD;
             septum) assessed by a large area of akinesia in the left ventricle (using DSE at&#xD;
             screening);&#xD;
&#xD;
          7. B-type natriuretic peptide (BNP) or NT pro-BNP is above the upper limit of normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-pregnant women who are not postmenopausal, surgically sterile or not practicing an&#xD;
             acceptable method of contraception. A female patient of child bearing potential, with&#xD;
             a positive serum or urine pregnancy test at screening visit #1. Females refusing to&#xD;
             exercise a reliable form of contraception;&#xD;
&#xD;
          2. Myocardial wall thickness of &lt;6 mm (millimeters) in the akinetic myocardial region to&#xD;
             be injected (using DSE at screening)&#xD;
&#xD;
          3. Inability to undergo a surgical biopsy of the skeletal muscle for culture of&#xD;
             myoblasts, including any significant myopathy;&#xD;
&#xD;
          4. Patient will require revascularization within six months;&#xD;
&#xD;
          5. Patients on continuous or intermittent intravenous drug therapy;&#xD;
&#xD;
          6. Not fitted, or fitted within less than 90 days prior to screening visit #1, with an&#xD;
             implantable cardioverter defibrillator (ICD);&#xD;
&#xD;
          7. Sustained ventricular tachycardia (VT), automatic implantable cardiodefibrillator&#xD;
             (AICD) firing, or ventricular fibrillation (VF) within 90 days prior to screening&#xD;
             visit #1;&#xD;
&#xD;
          8. Inability to perform a 6 minute walk test due to physical limitations other than HF&#xD;
             including:&#xD;
&#xD;
               1. Severe peripheral vascular disease, including aortic aneurysms, leading to&#xD;
                  limited claudication;&#xD;
&#xD;
               2. Severe pulmonary disease or chronic obstructive pulmonary disease (COPD) limiting&#xD;
                  exercise, dependence on chronic oral steroid therapy or previously requiring&#xD;
                  mechanical ventilation;&#xD;
&#xD;
               3. Stroke or transient ischemic attack leading to limitations in lower extremities&#xD;
                  or occurring within 180 days prior to screening visit #1;&#xD;
&#xD;
          9. MI, unstable angina or percutaneous coronary intervention (PCI) within 90 days prior&#xD;
             to screening;&#xD;
&#xD;
         10. having undergone CABG surgery within 150 days prior to screening visit #1;&#xD;
&#xD;
         11. Active myocarditis, constrictive pericarditis, restrictive, hypertrophic or congenital&#xD;
             cardiomyopathy;&#xD;
&#xD;
         12. Hemodynamically significant severe primary valvular heart disease, unless corrected by&#xD;
             a properly functional prosthetic valve;&#xD;
&#xD;
         13. Prior aortic valve replacement;&#xD;
&#xD;
         14. Systolic blood pressure (supine) ≤90 mmHg;&#xD;
&#xD;
         15. Resting heart rate &gt;100 bpm;&#xD;
&#xD;
         16. Severe uncontrolled HF including any evidence of severe fluid overload such as&#xD;
             peripheral edema &gt;+2 or rales ≥1/3 the lungs' height, need for intravenous therapy for&#xD;
             HF within 60 days of screening visit #1 or hospitalization for HF within 90 days of&#xD;
             screening visit #1;&#xD;
&#xD;
         17. Patient scheduled to receive cardiac resynchronization therapy (CRT) during the study;&#xD;
&#xD;
         18. Expected to receive or received a cardiac transplant, surgical remodeling procedure,&#xD;
             left ventricular assist device or cardiomyoplasty;&#xD;
&#xD;
         19. Six-minute walk test (6MWT) of &gt;400 meters or Minnesota Living With Heart Failure&#xD;
             (MLWHF) score of &lt;20;&#xD;
&#xD;
         20. Hematocrit (HCT) concentration below 30% (males) or below 27% (females);&#xD;
&#xD;
         21. Serum creatinine greater than 2.5 mg/dL (milligrams per deciliter) or end stage renal&#xD;
             disease;&#xD;
&#xD;
         22. Left ventricular mural thrombus;&#xD;
&#xD;
         23. Known sensitivity to gentamicin sulfate; or severe adverse reaction to nonionic&#xD;
             radiocontrast agents;&#xD;
&#xD;
         24. Active infectious disease and/or known to have tested positive for human&#xD;
             immunodeficiency virus (HIV), human t lymphotrophic virus (HTLV), hepatitis B virus&#xD;
             (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV); immunoglobulin M [IgM], and/or&#xD;
             syphilis. If the panel includes antibodies to the HBV core antigen (HBV-cAg) and&#xD;
             hepatitis B surface antigen (HBV-sAg), then an expert will be consulted as to&#xD;
             patient's eligibility based on the patient's infectious status;&#xD;
&#xD;
         25. Patients have undergone enhanced external pulsation (EECP) tratment within the last 6&#xD;
             months;&#xD;
&#xD;
         26. Exposure to any previous experimental angiogenic therapy and/or myocardial laser&#xD;
             therapy, or therapy with another investigational drug within 60 days of screening&#xD;
             visit #1 or enrollment in any concurrent study that may confound the results of this&#xD;
             study;&#xD;
&#xD;
         27. Known drug or alcohol dependence or any other factors which will interfere with the&#xD;
             study conduct or interpretation of the results or in the opinion of the investigator&#xD;
             are not suitable to participate;&#xD;
&#xD;
         28. Any illness other than CHF which might reduce life expectancy to less than 1 year from&#xD;
             screening visit #1;&#xD;
&#xD;
         29. Recent initiation of cardiac resynchronization therapy via placement of a&#xD;
             bi-ventricular pacemaker or bi-ventricular AICD within 180 days of study enrollment;&#xD;
             and&#xD;
&#xD;
        30 Unwilling and/or not able to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jim Moran Heart and Vascular Research Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Center Cardiovascular Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory/Crawford Long</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Research Institute/ACRI</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RUSH University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gagnon Heart Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stern Cardiology</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bioheartinc.com</url>
    <description>Bioheart Inc. website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <name_title>Warren Sherman, MN</name_title>
    <organization>Center for Interventional Vascular Therapy</organization>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>CHF</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Heart Attack</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Myoblast</keyword>
  <keyword>Bioheart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

